20 LATEST RESOURCES (86 INDEXED)
Ketamine for Adults with Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update · January 2024
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder · July 2022
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Methadone Treatment for Opioid Use Disorder – Improving Access through Regulatory and Legal Change: Proceedings of a Workshop (Meetings-Events) · July 2022
Publications (Books-Reports)
National Academies Press
OROS-Methylphenidate to Reduce ADHD Symptoms in Male Prisoners Aged 16-25 Years: A RCT · July 2022
Publications (Books-Reports)
National Institute for Health and Care Research
Monitoring Patients with Psychotic Disorders for Clozapine-Induced Myocarditis or Cardiomyopathy · June 2022
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics (Disruptive Psychopharmacology) · March 2022
Publications (Chapters)
NCBI>Current Topics in Behavioral Neurosciences
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee · February 2022
Publications (Books-Reports)
NCBI>Neurology
Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings · December 2021
Publications (Books-Reports)
Substance Abuse and Mental Health Services Administration
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia) · April 2021
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Bupropion for Treatment Resistant Depression · April 2021
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Nicotine Replacement Treatment, E-Cigarettes and an Online Behavioural Intervention to Reduce Relapse in Recent Ex-Smokers: A Multinational Four-Arm RCT · December 2020
Publications (Books-Reports)
National Institute for Health Research
Fluoxetine to Improve Functional Outcomes in Patients After Acute Stroke: The FOCUS RCT · May 2020
Publications (Books-Reports)
National Institute for Health Research
Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · February 2020
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · February 2020
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: A Review of Comparative Clinical and Cost-Effectiveness, and Guidelines · December 2019
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Administration of Naloxone in a Home or Community Setting: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines · December 2019
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Antidepressant Treatment with Sertraline for Adults with Depressive Symptoms in Primary Care: The PANDA Research Programme Including RCT · December 2019
Publications (Books-Reports)
National Institute for Health Research
Administration of Naloxone in a Home or Community Setting: A Rapid Qualitative Review · December 2019
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
E-Cigarettes Compared with Nicotine Replacement Therapy within the UK Stop Smoking Services: The TEC RCT · August 2019
Publications (Books-Reports)
National Institute for Health Research
Buprenorphine-Naloxone Sublingual Film versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · July 2019
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health